Table 3.
Therapeutic responses
| Therapy typea | Utilization (n (%)) | Effectiveness (n (%)) | Any neurodiagnostic abnormality vs normal workup | ||||
|---|---|---|---|---|---|---|---|
| All patients (n = 72) | Any neurodiagnostic abnormality (n = 29) | EEG/MRI/CSF normal (n = 43) | X2 value | p value | Odds ratio (95%CI) | ||
| Antidepressant | 45 (63%) | 22 (49%) | 4/16 (25%) | 18/29 (62%) | 5.67 | 0.02 | 0.20 (0.05–0.79) |
| Antipsychotic | 52 (72%) | 32 (61%) | 9/19 (47%) | 23/33 (70%) | 2.54 | 0.12 | 0.39 (0.12–1.26) |
| Benzodiazepines | 63 (87%) | 49 (77%) | 18/24 (75%) | 31/39 (79%) | 0.17 | 0.42 | 0.77 (0.23–2.59) |
| ECT | 49 (68%) | 36 (74%) | 6/15 (40%) | 30/34 (88%) | 12.42 | 0.01 | 0.09 (0.02–0.39) |
| Nutritional therapy | 29 (40%) | 0 (0%) | 0/13 (0%) | 0/10 (0%) | 0 | 1.0 | n/a |
|
Immunotherapy Steroids IVIg Anti-CD20 MMF/AZ |
43 (59%) 39 (54%) 43 (59%) 19 (26%) 19 (26%) |
74/120 (62%) 14/39 (36%) 38/43 (88%) 9/19 (47%) 13/19 (68%) |
55/74 (74%) 10/24 (42%) 24/26 (92%) 9/11 (81%) 12/13 (92%) |
19/46 (41%) 4/15 (27%) 14/17 (82%) 0/8 (0%) 1/6 (17%) |
10.04 0.90 0.05 9.89 12.17 |
< 0.001 0.34 0.33 0.01 0.01 |
4.11 (1.88–9.02) 1.96 (0.48–7.99) 2.57 (0.38–17.31) 49.5 (3.84–638.43) 60.0 (3.10–1159.84) |
AZ Azathioprine, CSF cerebrospinal fluid, EEG electroencephalogram, ECT electroconvulsive therapy, MRI magnetic resonance imaging, MMF mycophenolate mofetil
aPatients may have received multiple therapeutic interventions creating a higher “n” with regard to the treatment interventions by class